Given that the same cardiotoxicity surveillance recommendations originally established for HER2-positive breast cancer are now being applied in other treatment settings (i.e., lung or esophageal cancer), our effort to optimize the approach for cardiotoxicity surveillance will impact a growing number of cancer patients receiving HER2-targeted treatment. This evidence concerns the gene ERBB2 and breast carcinoma.